KR20020045569A - 수난용성 약물의 서방성 제형 조성물 - Google Patents
수난용성 약물의 서방성 제형 조성물 Download PDFInfo
- Publication number
- KR20020045569A KR20020045569A KR1020010077044A KR20010077044A KR20020045569A KR 20020045569 A KR20020045569 A KR 20020045569A KR 1020010077044 A KR1020010077044 A KR 1020010077044A KR 20010077044 A KR20010077044 A KR 20010077044A KR 20020045569 A KR20020045569 A KR 20020045569A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- polyethylene glycol
- drug
- poorly water
- liquid polyethylene
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 229940079593 drug Drugs 0.000 title claims abstract description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 12
- 230000002459 sustained effect Effects 0.000 title description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 86
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 63
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 56
- 229920000642 polymer Polymers 0.000 claims abstract description 32
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 25
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 25
- 229920000359 diblock copolymer Polymers 0.000 claims abstract description 24
- 239000000693 micelle Substances 0.000 claims abstract description 24
- 238000009472 formulation Methods 0.000 claims abstract description 19
- 239000007943 implant Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 16
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 13
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920001610 polycaprolactone Polymers 0.000 claims abstract description 9
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000013268 sustained release Methods 0.000 claims abstract description 8
- 239000012730 sustained-release form Substances 0.000 claims abstract description 8
- 239000004632 polycaprolactone Substances 0.000 claims abstract description 6
- 229920001400 block copolymer Polymers 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 34
- 229920001577 copolymer Polymers 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 10
- 229930012538 Paclitaxel Natural products 0.000 claims description 9
- 229960001592 paclitaxel Drugs 0.000 claims description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 9
- 238000012377 drug delivery Methods 0.000 claims description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 5
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 3
- -1 polyethylene Polymers 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 238000007599 discharging Methods 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229920001427 mPEG Polymers 0.000 description 8
- 125000005474 octanoate group Chemical group 0.000 description 8
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 8
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 7
- 241000555081 Stanus Species 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940089151 indomethacin 20 mg Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000382 poly(ethylene glycol) methyl ether-block-poly(L-lactide-co-glycolide) Polymers 0.000 description 2
- 238000000710 polymer precipitation Methods 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241001510071 Pyrrhocoridae Species 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- GHPGOEFPKIHBNM-UHFFFAOYSA-N antimony(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Sb+3].[Sb+3] GHPGOEFPKIHBNM-UHFFFAOYSA-N 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
실시/비교예 | 양친성 블록공중합체 | 약물 | PEG | 고분자 매트릭스* |
실시예 1 | mPEG-PLA(MW 2,000-1,800)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 300) 200 ㎎ | PLA 100 ㎎ |
실시예 2 | mPEG-PLA(MW 2,000-1,800)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 300) 300 ㎎ | PLA 100 ㎎ |
실시예 3 | mPEG-PLA(MW 2,000-1,800)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 600) 400 ㎎ | PLA 300 ㎎ |
실시예 4 | mPEG-PLA(MW 2,000-1,800)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 600) 400 ㎎ | PLA 600 ㎎ |
실시예 5 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 300) 400 ㎎ | PLA 300 ㎎ |
실시예 6 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 300) 400 ㎎ | PLA 600 ㎎ |
실시예 7 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 300) 400 ㎎ | PLA 900 ㎎ |
실시예 8 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 300) 400 ㎎ | PLA 1,200 ㎎ |
실시예 9 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 300) 600 ㎎ | PLA 1,200 ㎎ |
실시예 10 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 600) 400 ㎎ | PLA 600 ㎎ |
실시예 11 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 800) 400 ㎎ | PLA 600 ㎎ |
실시예 12 | mPEG-PLA(MW 3,400-2,500)95 ㎎ | 파클리탁셀5 ㎎ | PEG(MW 300) 400 ㎎ | PLGA 600 ㎎ |
실시예 13 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 인도메타신10 ㎎ | PEG(MW 300) 400 ㎎ | PLA 600 ㎎ |
실시예 14 | mPEG-PLA(MW 3,400-2,500)90 ㎎ | 인도메타신10 ㎎ | PEG(MW 300) 400 ㎎ | PLA 900 ㎎ |
실시예 15 | mPEG-PLA(MW 5,000-4,000)80 ㎎ | 인도메타신20 ㎎ | PEG(MW 800) 400 ㎎ | PLA 900 ㎎ |
실시예 16 | mPEG-PCL(MW 5,000-4,000)80 ㎎ | 인도메타신20 ㎎ | PEG(MW 300) 400 ㎎ | PLA 900 ㎎ |
실시예 17 | mPEG-PLGA(MW 5,000-4,000, LA/GA=7/3) 90 ㎎ | 사이클로스포린A10 ㎎ | PEG(MW 300) 400 ㎎ | PLA 600 ㎎ |
실시예 18 | mPEG-PLDO(MW 5,000-4,000, LA/DO=7/3) 95 ㎎ | 파클리탁셀5 ㎎ | PEG(MW 300) 400 ㎎ | PLGA 300 ㎎ |
비교예 1 | - | 파클리탁셀10 ㎎ | PEG(MW 600) 400 ㎎ | PLA 300 ㎎ |
비교예 2 | mPEG-PLA(MW 2,000-1,800)90 ㎎ | 파클리탁셀10 ㎎ | PEG(MW 600) 400 ㎎ | - |
실시예 | 누적 방출량(%) | ||||||
0 일 | 1 일 | 2 일 | 3 일 | 5 일 | 7 일 | 10 일 | |
1 | 0 | 33 | 40 | 54 | 65 | 72 | 85 |
2 | 0 | 36 | 47 | 57 | 68 | 76 | 90 |
3 | 0 | 31 | 40 | 51 | 62 | 70 | 82 |
4 | 0 | 23 | 33 | 45 | 53 | 65 | 70 |
5 | 0 | 25 | 36 | 45 | 57 | 68 | 78 |
6 | 0 | 21 | 35 | 42 | 48 | 57 | 65 |
7 | 0 | 18 | 28 | 37 | 42 | 49 | 53 |
8 | 0 | 17 | 24 | 33 | 38 | 42 | 45 |
9 | 0 | 18 | 30 | 40 | 45 | 53 | 57 |
10 | 0 | 21 | 31 | 42 | 47 | 57 | 62 |
11 | 0 | 20 | 31 | 40 | 47 | 55 | 60 |
12 | 0 | 23 | 34 | 46 | 51 | 62 | 69 |
13 | 0 | 23 | 33 | 45 | 55 | 65 | 71 |
14 | 0 | 17 | 31 | 38 | 47 | 53 | 58 |
15 | 0 | 17 | 25 | 33 | 38 | 45 | 50 |
16 | 0 | 18 | 28 | 35 | 43 | 49 | 55 |
17 | 0 | 19 | 30 | 38 | 47 | 53 | 57 |
18 | 0 | 18 | 31 | 38 | 49 | 55 | 60 |
비교예 1 | 0 | 2 | 2 | 3 | 3 | 3 | 4 |
비교예 2 | 0 | 100 | - | - | - | - | - |
조성 | 투여방법 | 투여용량 | 마리수 | |
대조군 | - | 무처리 | - | 6 |
비히클(vehicle) | 약물을 함유하지 않은실시예 1의 조성물 | 암조직내(it) | - | 6 |
시판제형(iv) | 시판제형의 조성물 | 정맥내(iv) | 20 ㎎/㎏×3 회 | 6 |
시험군(it) | 실시예 1의 조성물 | 암조직내(it) | 20 ㎎/㎏ | 6 |
조성 | 투여방법 | 투여용량 | 마리수 | |
대조군 | - | 무처리 | - | 6 |
비히클(vehicle) | 약물을 함유하지 않은실시예 1의 조성물 | 암조직내(it) | - | 6 |
시판제형(iv) | 시판제형의 조성물 | 정맥내(iv) | 20 ㎎/㎏×3 회 | 6 |
시험군(it) | 실시예 1의 조성물 | 암조직내(it) | 60 ㎎/㎏ | 6 |
Claims (16)
- ⅰ) 양친성 이중블록 공중합체;ⅱ) 수난용성 약물;ⅲ) 생분해성 고분자 물질; 및,ⅳ) 액상 폴리에틸렌글리콜:을 포함하는 약물 전달체용 서방성 제형의 조성물.
- 제1항에 있어서, 상기 조성물은 체내 주입시 임플란트를 형성하고, 상기 양친성 이중블록 공중합체는 액상 폴리에틸렌글리콜내에서 고분자 미셀을 형성하여 수난용성 약물을 함유하고, 상기 생분해성 고분자 물질은 액상 폴리에틸렌글리콜내에서 매트릭스를 형성하여 약물-함유 미셀을 함유하는 조성물.
- 제1항에 있어서, 상기 양친성 이중블록 공중합체가 친수성 폴리에틸렌글리콜 블록 및 소수성 생분해성 고분자 블록으로 구성되는 블록 공중합체인 조성물.
- 제3항에 있어서, 상기 친수성 폴리에틸렌글리콜 블록이 폴리에틸렌글리콜, 모노알콕시폴리에틸렌글리콜 및 모노아실옥시폴리에틸렌글리콜로 구성된 군으로부터 선택되는 폴리에틸렌글리콜 유도체이고, 상기 소수성 생분해성 고분자 블록은 폴리락타이드, 폴리카프로락톤, 락타이드와 글라이콜라이드의 공중합체, 락타이드와 카프로락톤의 공중합체, 락타이드와 파라디옥사논의 공중합체, 폴리오르소에스터, 폴리안하이드라이드, 폴리아미노산 및 폴리카보네이트로 구성된 군으로부터 선택되는 것인 조성물.
- 제3항에 있어서, 상기 친수성 폴리에틸렌글리콜 블록 및 상기 소수성 생분해성 고분자 블록의 분자량이 각각 500∼20,000 달톤인 조성물.
- 제1항에 있어서, 상기 양친성 이중블록 공중합체의 함량이 전체 조성물에 대하여 3∼70 중량%인 조성물.
- 제1항에 있어서, 상기 수난용성 약물은 물에 대한 용해도가 10 mg/㎖ 이하인 항암제, 항균제, 스테로이드류, 소염진통제, 성호르몬, 면역억제제, 항바이러스제, 마취제, 항구토제 또는 항히스타민제인 조성물.
- 제7항에 있어서, 상기 수난용성 약물이 파클리탁셀, 도세탁셀, 독소루비신, 시스플레틴, 카보플래틴, 5-FU, 에토포시드, 캄토테신, 테스토스테론, 에스트로젠, 에스트라다이올, 트리암시놀론 아세토나이드, 하이드로코티손, 덱사메타손, 프레드니솔론, 베타메타손, 사이클로스포린 및 프로스타글란딘으로 구성된 군으로부터 선택되는 조성물.
- 제1항에 있어서, 상기 수난용성 약물의 함량이 양친성 이중블록 공중합체에 대하여 0.1∼50 중량%인 조성물.
- 제1항에 있어서, 상기 생분해성 고분자 물질이 폴리락타이드, 폴리카프로락톤, 락타이드와 글리콜라이드의 공중합체 또는 이들의 혼합물인 조성물.
- 제1항에 있어서, 상기 생분해성 고분자 물질의 함량이 전체 조성물에 대하여 5∼80 중량%인 조성물.
- 제1항에 있어서, 생분해성 고분자 물질의 분자량이 500∼50,000 달톤인 조성물.
- 제1항에 있어서, 상기 액상 폴리에틸렌글리콜의 함량이 전체 조성물에 대하여 5∼80 중량%인 조성물.
- 제1항에 있어서, 상기 액상 폴리에틸렌글리콜의 분자량이 100∼3,000 달톤인 조성물.
- 제1항에 있어서, 상기 액상 폴리에틸렌글리콜이 액상 폴리에틸렌글리콜, 액상 폴리에틸렌글리콜의 알킬 유도체 및 액상 폴리에틸렌글리콜의 알릴 유도체로 구성된 군으로부터 선택된 하나 이상의 것인 조성물.
- ⅰ) 액상 폴리에틸렌글리콜, 양친성 이중블록 공중합체 및 수난용성 약물을 혼합하여 고분자 미셀 폴리에틸렌글리콜 액체 조성물을 제조하는 단계;ⅱ) 생분해성 고분자 물질을 액상 폴리에틸렌글리콜에 용해 또는 분산시켜 생분해성 고분자 액체 조성물을 제조하는 단계; 및,ⅲ) 단계 ⅰ) 및 ⅱ)의 액체 조성물을 혼합하는 단계:를 포함하는, 제1항 내지 제15항중 어느 한 항에 따른 조성물의 제조방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000074098 | 2000-12-07 | ||
KR20000074098 | 2000-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020045569A true KR20020045569A (ko) | 2002-06-19 |
KR100446101B1 KR100446101B1 (ko) | 2004-08-30 |
Family
ID=19702771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0077044A KR100446101B1 (ko) | 2000-12-07 | 2001-12-06 | 수난용성 약물의 서방성 제형 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7153520B2 (ko) |
EP (1) | EP1339389B1 (ko) |
JP (1) | JP2004514734A (ko) |
KR (1) | KR100446101B1 (ko) |
CN (1) | CN1234416C (ko) |
AT (1) | ATE405251T1 (ko) |
AU (2) | AU2273302A (ko) |
CA (1) | CA2430481C (ko) |
DE (1) | DE60135486D1 (ko) |
WO (1) | WO2002045689A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009091150A3 (en) * | 2007-12-31 | 2009-10-22 | Samyang Corporation | Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof |
KR20190122004A (ko) * | 2018-04-19 | 2019-10-29 | 중앙대학교 산학협력단 | 항암제 봉입 마이셀 제제 조성물 |
WO2022045823A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 바임 | 생분해성 고분자 분산체, 이를 포함하는 조성물 및 피부 개선용 시스템 |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050042194A1 (en) * | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
CN1325046C (zh) * | 2001-08-31 | 2007-07-11 | 麦吉尔大学 | 可生物降解的多聚纳米微囊及其应用 |
CA2463172C (en) * | 2001-10-18 | 2009-08-18 | Samyang Corporation | Polymeric micelle composition with improved stability |
US7649023B2 (en) | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
WO2004011054A2 (en) | 2002-07-31 | 2004-02-05 | Alza Corporation | Injectable multimodal polymer depot compositions and uses thereof |
US8986737B2 (en) | 2002-09-05 | 2015-03-24 | Wm. Marsh Rice University | Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth |
CA2497973C (en) * | 2002-09-05 | 2012-11-06 | Catherine G. Ambrose | Antibiotic microspheres for treatment of infections and osteomyelitis |
DE60319727T2 (de) * | 2002-10-21 | 2009-03-12 | L'oreal | Verfahren zum auflösen lipophiler verbindungen, und kosmetische zusammensetzung. |
AU2004241830B9 (en) * | 2003-05-26 | 2010-04-22 | Hiroshi Maeda | Antitumor agent and process for producing the same |
CN101862455A (zh) | 2003-06-26 | 2010-10-20 | 普西维达公司 | 原位胶凝的药物递送系统 |
AR047552A1 (es) | 2003-06-26 | 2006-01-25 | Control Delivery Sys Inc | Sistemas de suministro de farmacos de liberacion sostenida biodegradables |
JP4939936B2 (ja) * | 2003-06-27 | 2012-05-30 | 株式會社アモーレパシフィック | 生理活性成分を含有する自己集合性高分子ナノ粒子の製造方法、及び得られた自己集合性高分子ナノ粒子を含有する外用剤組成物 |
WO2005000258A1 (en) * | 2003-06-27 | 2005-01-06 | Amorepacific Corporation | Self-assembled polymeric nanoparticles containing physiologically active ingredients and external application containing the nanoparticles |
KR101054728B1 (ko) | 2004-06-16 | 2011-08-05 | (주)아모레퍼시픽 | 난용성 발모 및 육모 생리활성 물질인 사이클로스포린을포함하는 나노입자 및 이를 함유하는 피부 외용제 조성물 |
KR100967113B1 (ko) | 2003-12-03 | 2010-07-05 | (주)아모레퍼시픽 | 코엔자임 q10을 함유한 자기회합성 고분자 나노입자 및이를 함유한 피부 외용제 조성물 |
KR20050064075A (ko) * | 2003-12-23 | 2005-06-29 | 주식회사 삼양사 | 이트라코나졸을 유효성분으로 하는 약학적 조성물 |
GB0412866D0 (en) * | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
US8980300B2 (en) | 2004-08-05 | 2015-03-17 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
US20060034889A1 (en) * | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
CA2585754C (en) | 2004-11-02 | 2014-12-23 | Tel-Aviv University Future Technology Development L.P. | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy |
EP2348096A3 (en) * | 2005-01-04 | 2011-11-09 | Intezyne Technologies Inc. | Synthesis of hybrid block copolymers and uses thereof |
JP2007023023A (ja) * | 2005-06-15 | 2007-02-01 | Kanagawa Acad Of Sci & Technol | 組織接着性薬剤放出ゲル形成用組成物 |
EP2063970A1 (en) * | 2006-09-19 | 2009-06-03 | FUJIFILM Manufacturing Europe B.V. | Preparation of fine particles |
JP2010504318A (ja) * | 2006-09-22 | 2010-02-12 | ラボファーム インコーポレイテッド | pH標的化薬剤送達のための組成物及び方法 |
KR100946275B1 (ko) * | 2006-09-26 | 2010-03-08 | 주식회사 삼양사 | 수 난용성 캄토테신 유도체의 미세 나노입자 및 그의제조방법 |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
GB0714223D0 (en) * | 2007-07-20 | 2007-08-29 | Fujifilm Mfg Europe Bv | Preparation of fine particles |
GB0720716D0 (en) * | 2007-10-23 | 2007-12-05 | York Pharma Plc | Novel formulation |
US8642062B2 (en) * | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
WO2009064442A1 (en) | 2007-11-13 | 2009-05-22 | Brookwood Pharmaceuticals, Inc. | Viscous terpolymers as drug delivery platform |
US9801818B2 (en) | 2007-12-31 | 2017-10-31 | Samyang Biopharmaceuticals Corporation | Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug |
KR101024742B1 (ko) * | 2007-12-31 | 2011-03-24 | 주식회사 삼양사 | 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법 |
CN101909601B (zh) * | 2008-01-18 | 2013-06-26 | 陶氏环球技术公司 | 使用甲氧基聚乙二醇增强难溶性活性剂的水溶解度的方法 |
CN101932311B (zh) | 2008-02-22 | 2014-07-16 | 东丽株式会社 | 微粒及其药物组合物 |
US8858995B2 (en) * | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
EP2103313A1 (en) * | 2008-03-19 | 2009-09-23 | Koninklijke Philips Electronics N.V. | Method for the synthesis of hollow spheres |
TWI388591B (zh) * | 2008-03-28 | 2013-03-11 | Ind Tech Res Inst | 溫度敏感性材料 |
US8916188B2 (en) | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
WO2010005725A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
PT2323623T (pt) | 2008-08-12 | 2016-11-04 | Novartis Ag | Composições farmacêuticas |
EP2172189A1 (en) * | 2008-10-01 | 2010-04-07 | Novartis AG | Pharmaceutical Compositions |
JP2010065067A (ja) * | 2008-09-08 | 2010-03-25 | Tokyo Univ Of Agriculture & Technology | 粒子およびその製造方法、ならびにゲル |
CA2738766A1 (en) * | 2008-09-25 | 2010-04-01 | Invivo Therapeutics Corporation | Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents |
EP2370064A4 (en) * | 2008-12-11 | 2012-09-19 | A P Pharma Inc | METHOD FOR INCREASING THE STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS |
TWI372057B (en) * | 2008-12-11 | 2012-09-11 | Dev Center Biotechnology | Sustained release implant for granisetron |
WO2010075072A2 (en) | 2008-12-15 | 2010-07-01 | Bind Biosciences | Long circulating nanoparticles for sustained release of therapeutic agents |
US8951546B2 (en) | 2008-12-23 | 2015-02-10 | Surmodics Pharmaceuticals, Inc. | Flexible implantable composites and implants comprising same |
US20100158978A1 (en) * | 2008-12-23 | 2010-06-24 | Peter Markland | Bioactive spray coating compositions and methods of making and uses thereof |
US9415197B2 (en) | 2008-12-23 | 2016-08-16 | Surmodics, Inc. | Implantable suction cup composites and implants comprising same |
US9480643B2 (en) * | 2008-12-23 | 2016-11-01 | Surmodics Pharmaceuticals, Inc. | Implantable composites and implants comprising same |
US8974808B2 (en) | 2008-12-23 | 2015-03-10 | Surmodics, Inc. | Elastic implantable composites and implants comprising same |
EP2201935B1 (en) * | 2008-12-26 | 2020-07-08 | Samyang Biopharmaceuticals Corporation | Polymeric micelle composition containing a poorly soluble drug and preparation method of the same |
TWI374903B (en) * | 2008-12-31 | 2012-10-21 | Ind Tech Res Inst | Biodegradable copolymer hydrogel materials |
US20100203150A1 (en) * | 2009-02-06 | 2010-08-12 | National Tsing Hua University | Novel amphiphilic copolymers and fabrication method thereof |
WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
CA2756072A1 (en) * | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
CA2940931C (en) | 2009-10-01 | 2019-04-30 | Adare Pharmaceuticals, Inc. | Orally administered corticosteroid compositions |
EP2509634B1 (en) | 2009-12-11 | 2019-03-06 | Pfizer Inc | Stable formulations for lyophilizing therapeutic particles |
JP5965844B2 (ja) * | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物 |
US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
WO2012030819A1 (en) | 2010-08-30 | 2012-03-08 | Surmodics Pharmaceuticals, Inc. | Terpolymers as pressure-sensitive adhesives |
PT2658525T (pt) | 2010-12-29 | 2017-11-30 | Medincell | Composições biodegradáveis de entrega de fármaco |
WO2012177825A1 (en) | 2011-06-21 | 2012-12-27 | Bvw Holding Ag | Medical device comprising boswellic acid |
WO2013148682A1 (en) * | 2012-03-26 | 2013-10-03 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
CU24287B1 (es) * | 2012-06-27 | 2017-12-08 | Medincell | Suministro de fármaco biodegradable para las composiciones hidrofóbicas |
ES2732377T3 (es) | 2012-09-17 | 2019-11-22 | Pfizer | Procedimiento de preparación de nanopartículas terapéuticas |
US20150104520A1 (en) * | 2013-04-05 | 2015-04-16 | Vuong Trieu | Nanoparticle Formulations in Biomarker Detection |
WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
CN104758256B (zh) * | 2014-02-14 | 2016-05-04 | 苏州海特比奥生物技术有限公司 | 一种多西他赛纳米聚合物胶束冻干制剂及其制备方法 |
BR112016021130A2 (pt) | 2014-03-14 | 2017-08-15 | Pfizer | Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas |
WO2016205652A1 (en) * | 2015-06-18 | 2016-12-22 | Acuitybio Corporation | Implantable drug delivery compositions and methods of use thereof |
PT3377041T (pt) | 2015-11-16 | 2023-12-15 | Maria Pereira Da Cruz Alves Garcia | Método para morcelação e/ou direcionamento de princípios farmaceuticamente ativos ao tecido sinovial |
TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
CN106727306A (zh) * | 2016-12-12 | 2017-05-31 | 温州医科大学 | 一种高载药量曲安奈德胶束的制备方法 |
CN107596380B (zh) * | 2017-09-03 | 2020-09-11 | 河南师范大学 | 基于聚乙二醇-聚碳酸酯的还原敏感性喜树碱前药及其制备方法和应用 |
WO2021146215A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
CN114903904B (zh) * | 2021-02-08 | 2024-02-09 | 宜昌人福药业有限责任公司 | 瑞马唑仑药用盐和阿片样物质的注射用药物组合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2080682B (en) * | 1980-07-30 | 1984-03-28 | Ciba Geigy Ag | Antiherpetically active lipstick |
CA2050067C (en) * | 1990-08-30 | 2000-05-30 | Yasushi Morita | Controlled drug release composition |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
JPH08176016A (ja) * | 1994-12-19 | 1996-07-09 | Univ Miami | 生分解可能で注射可能な薬物運搬ポリマー |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US20020164374A1 (en) * | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
KR100289074B1 (ko) * | 1998-02-04 | 2001-07-12 | 김윤 | 난용성약물함유시스템 |
US7128927B1 (en) * | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
KR100274842B1 (ko) * | 1998-10-01 | 2001-03-02 | 김효근 | 미립구를 이용한 레티노익산의 서방형 약물방출 시스템 |
KR100360827B1 (ko) * | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
US7550157B2 (en) * | 2000-05-12 | 2009-06-23 | Samyang Corporation | Method for the preparation of polymeric micelle via phase separation of block copolymer |
US7217770B2 (en) * | 2000-05-17 | 2007-05-15 | Samyang Corporation | Stable polymeric micelle-type drug composition and method for the preparation thereof |
-
2001
- 2001-12-06 KR KR10-2001-0077044A patent/KR100446101B1/ko active IP Right Grant
- 2001-12-07 WO PCT/KR2001/002121 patent/WO2002045689A1/en active IP Right Grant
- 2001-12-07 US US10/416,980 patent/US7153520B2/en not_active Expired - Lifetime
- 2001-12-07 EP EP01999357A patent/EP1339389B1/en not_active Expired - Lifetime
- 2001-12-07 CA CA002430481A patent/CA2430481C/en not_active Expired - Lifetime
- 2001-12-07 AU AU2273302A patent/AU2273302A/xx active Pending
- 2001-12-07 AT AT01999357T patent/ATE405251T1/de not_active IP Right Cessation
- 2001-12-07 CN CNB018195784A patent/CN1234416C/zh not_active Expired - Fee Related
- 2001-12-07 AU AU2002222733A patent/AU2002222733B2/en not_active Ceased
- 2001-12-07 JP JP2002547475A patent/JP2004514734A/ja active Pending
- 2001-12-07 DE DE60135486T patent/DE60135486D1/de not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009091150A3 (en) * | 2007-12-31 | 2009-10-22 | Samyang Corporation | Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof |
AU2008347720B2 (en) * | 2007-12-31 | 2011-07-28 | Samyang Holdings Corporation | Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof |
AU2008347720C1 (en) * | 2007-12-31 | 2012-01-19 | Samyang Holdings Corporation | Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof |
RU2459840C2 (ru) * | 2007-12-31 | 2012-08-27 | Самъянг Корпорейшн | АМФИФИЛЬНЫЙ СОПОЛИМЕР ВЫСОКОЙ ЧИСТОТЫ, СОДЕРЖАЩИЙ ГИДРОФОБНЫЙ БЛОК ИЗ α-ГИДРОКСИКИСЛОТЫ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ |
US8853351B2 (en) | 2007-12-31 | 2014-10-07 | Samyang Biopharmaceuticals Corporation | Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof |
KR20190122004A (ko) * | 2018-04-19 | 2019-10-29 | 중앙대학교 산학협력단 | 항암제 봉입 마이셀 제제 조성물 |
WO2022045823A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 바임 | 생분해성 고분자 분산체, 이를 포함하는 조성물 및 피부 개선용 시스템 |
Also Published As
Publication number | Publication date |
---|---|
EP1339389A1 (en) | 2003-09-03 |
CN1477952A (zh) | 2004-02-25 |
EP1339389A4 (en) | 2007-08-08 |
ATE405251T1 (de) | 2008-09-15 |
CA2430481A1 (en) | 2002-06-13 |
EP1339389B1 (en) | 2008-08-20 |
WO2002045689A1 (en) | 2002-06-13 |
CA2430481C (en) | 2008-07-22 |
DE60135486D1 (de) | 2008-10-02 |
AU2273302A (en) | 2002-06-18 |
US7153520B2 (en) | 2006-12-26 |
JP2004514734A (ja) | 2004-05-20 |
KR100446101B1 (ko) | 2004-08-30 |
CN1234416C (zh) | 2006-01-04 |
AU2002222733B2 (en) | 2006-03-30 |
US20040037885A1 (en) | 2004-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100446101B1 (ko) | 수난용성 약물의 서방성 제형 조성물 | |
AU2002222733A1 (en) | Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof | |
KR100421451B1 (ko) | 안정한 고분자 미셀 조성물 및 그의 제조방법 | |
Burt et al. | Development of copolymers of poly (D, L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel | |
JP5121790B2 (ja) | 薬剤送達のための生物分解性ブロックコポリマー組成物 | |
KR100360827B1 (ko) | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 | |
US7875677B2 (en) | Micellar drug delivery systems for hydrophobic drugs | |
AU2001262756A1 (en) | Stable polymeric micelle-type drug composition and method for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120531 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20130531 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150626 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160601 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170605 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20180605 Year of fee payment: 15 |